19 July 2018
Visiongain’ has launched a new Pharmaceutical Report Vaccine Sales Market Forecast 2018-2028: Paediatric Vaccines, Adult Vaccines, Elderly Vaccines, Travel Vaccines, Therapeutic Vaccines, Prevnar, Gardasil, Fluzone, Pentacel, ProQuad, Infanrix/Pediarix, Zostavax, RotaTeq, Menactra
A new report by visiongain forecasts that overall sales of human vaccines will reach $61.1 billion worldwide in 2022. That revenue growth will continue steadily through to 2028, especially with advances in vaccine technology. That revenue prediction and others appear in Vaccine Sales Market Forecast 2018-2028: Paediatric Vaccines, Adult Vaccines, Elderly Vaccines, Travel Vaccines, Therapeutic Vaccines, Prevnar, Gardasil, Fluzone, Pentacel, ProQuad, Infanrix/Pediarix, Zostavax, RotaTeq, Menactra
“Vaccinations save billions of dollars each year by avoiding vaccine-preventable infections and reducing the disease and economic burden globally. As the world moves towards an ageing population, the elderly become more susceptible to contracting infections owing to their pre-existing conditions and weaker immune system, thereby boosting the demand for vaccines. Furthermore, high birth rates with poor sanitary conditions, but increasingly improved health care systems and vaccination routines in the emerging markets will greatly fuel demand for vaccines.
Although the vaccine industry makes up a small segment for pharmaceutical companies, it represents a dynamic and robust growth market. With the increased awareness of the benefits of vaccinations across the world, the demand for immunisation programmes increases. Furthermore, developments in vaccine technology, delivery, efficacy and novel disease targeting will drive the long-term growth of the human vaccines industry.” – Pharmaceutical Industry Analyst
Visiongain’s new investigation gives individual revenue predictions to 2028 for four vaccine submarkets at world level:
• Paediatric vaccines
• Adult vaccines
• Elderly vaccines
• Travel vaccines.
That analysis also shows 10 revenue forecasts to 2028 for leading vaccines, including these:
• ProQuad/M-M-R- II/Varivax.
The study also shows prospects for vaccine sales in developed and developing regions, with individual revenue forecasts to 2028 for 11 countries:
• United States (US)
• Germany, France, United Kingdom, Italy and Spain
• Brazil, Russia, India and China.
In particular the analysis explores these six market leaders:
• Merck & Co.
• Johnson & Johnson
Visiongain’s updated report also analyses vaccines in research and development:
• Prophylactic vaccines
• Products for children
• Agents for protecting adults
• Treatments for older people
• Travel vaccination
• Therapeutic vaccines.
Vaccine Sales Market Forecast 2018-2028: Paediatric Vaccines, Adult Vaccines, Elderly Vaccines, Travel Vaccines, Therapeutic Vaccines, Prevnar, Gardasil, Fluzone, Pentacel, ProQuad, Infanrix/Pediarix, Zostavax, RotaTeq, Menactra adds to visiongain’s reports on industries and markets in healthcare. That portfolio covers pharmaceuticals, biotechnology, medical devices, diagnostics and outsourced services.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
As lockdowns were imposed in all the countries, diagnosis rates went down in majority of countries during the year hitting the drug sales for some period. Although lockdown measures have been eased up in most countries by mid-year 2020, this trend is expected to continue beyond 2020, stock up of medicines by patients is likely to propel the drug sales in majority of the developed economies, which account for majority of rare diseases.
02 March 2021
Product approval is a major milestone facing all key competitors in the respiratory inhalers market. Several strategies were implemented by key market players between 2015 and Jan 2021.
26 February 2021
The global bile duct cancer drug market has been growing considerably owing to the rising incidence and prevalence rate of bile duct cancer patients worldwide, technological advancement in drug development, and healthcare spending.
22 February 2021
The global Big Data Analytics in Healthcare market has been growing considerably owing to the rising technological advancement, growing investment, and cohesive government policies.